Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 90,164 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 90,164 shares of the stock in a transaction on Tuesday, November 4th. The shares were sold at an average price of $1.22, for a total transaction of $110,000.08. Following the completion of the sale, the director directly owned 3,853,195 shares of the company’s stock, valued at approximately $4,700,897.90. This trade represents a 2.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Luke Evnin also recently made the following trade(s):

• On Thursday, November 6th, Luke Evnin sold 34,947 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.21, for a total transaction of $42,285.87.
• On Wednesday, November 5th, Luke Evnin sold 30,774 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.22, for a total value of $37,544.28.
• On Monday, November 3rd, Luke Evnin sold 60,369 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.29, for a total transaction of $77,876.01.
• On Friday, October 31st, Luke Evnin sold 73,192 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.28, for a total value of $93,685.76.
• On Thursday, October 30th, Luke Evnin sold 55,795 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.43, for a total transaction of $79,786.85.
• On Wednesday, October 29th, Luke Evnin sold 86,154 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.55, for a total value of $133,538.70.
• On Tuesday, October 28th, Luke Evnin sold 44,327 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.64, for a total transaction of $72,696.28.
• On Monday, October 27th, Luke Evnin sold 46,664 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.72, for a total transaction of $80,262.08.

Werewolf Therapeutics Trading Down 1.6%

HOWL stock opened at $1.20 on Friday. Werewolf Therapeutics, Inc. has a one year low of $0.60 and a one year high of $2.41. The stock has a market cap of $58.25 million, a price-to-earnings ratio of -0.74 and a beta of 0.72. The company has a fifty day moving average price of $1.61 and a two-hundred day moving average price of $1.32. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 5.30.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.03. Equities analysts anticipate that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on HOWL. Zacks Research upgraded shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 16th. Bank of America reduced their price objective on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a report on Monday, August 25th. JMP Securities lowered their price target on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research report on Thursday, August 21st. Citigroup restated a “buy” rating on shares of Werewolf Therapeutics in a research note on Monday, August 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $8.00.

Hedge Funds Weigh In On Werewolf Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in HOWL. Bridgeway Capital Management LLC increased its stake in Werewolf Therapeutics by 157.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after purchasing an additional 62,414 shares during the period. Bank of America Corp DE increased its position in shares of Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after buying an additional 25,882 shares during the period. Jane Street Group LLC bought a new stake in shares of Werewolf Therapeutics during the second quarter valued at approximately $409,000. Qube Research & Technologies Ltd purchased a new stake in shares of Werewolf Therapeutics in the 2nd quarter worth about $48,000. Finally, Marshall Wace LLP bought a new position in shares of Werewolf Therapeutics during the second quarter valued at approximately $113,000. Institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.